Abstract
Vinca alkaloids and taxanes represent the mainstay of medical treatment of hematological and solid tumors. Unfortunately, a major clinical problem with these agents is drug resistance. Although a plethora of mechanisms of drug resistance have been described, only a few of them have been validated in clinical trials. Among these, the one involving the protein TUBB3 seems to represent a promising target for studying drug resistance. In fact, it seems that this protein is a factor promoting cell survival and represents an endogenous element of an inherent drug-resistance program built into cells to counteract the activity of microtubule-interacting drugs. Its pivotal role has been ascertained in clinical trials in lung, breast, and ovarian cancer, three diseases that can be successfully treated with microtubule-interacting drugs. Although TUBB3 is probably not a unique factor in drug resistance, the hope is that direct targeting of this protein will increase the response to microtubule-interacting drugs, thereby overcoming an important element in the growth of drug resistance.
Keywords: TUBB3, tubulin, drug resistance, taxanes, vinca alkaloids, ovarian cancer, lung cancer
Current Cancer Drug Targets
Title: Looking at Drug Resistance Mechanisms for Microtubule Interacting Drugs: Does TUBB3 Work?
Volume: 7 Issue: 8
Author(s): Cristiano Ferlini, Giuseppina Raspaglio, Lucia Cicchillitti, Simona Mozzetti, Silvia Prislei, Silvia Bartollino and Giovanni Scambia
Affiliation:
Keywords: TUBB3, tubulin, drug resistance, taxanes, vinca alkaloids, ovarian cancer, lung cancer
Abstract: Vinca alkaloids and taxanes represent the mainstay of medical treatment of hematological and solid tumors. Unfortunately, a major clinical problem with these agents is drug resistance. Although a plethora of mechanisms of drug resistance have been described, only a few of them have been validated in clinical trials. Among these, the one involving the protein TUBB3 seems to represent a promising target for studying drug resistance. In fact, it seems that this protein is a factor promoting cell survival and represents an endogenous element of an inherent drug-resistance program built into cells to counteract the activity of microtubule-interacting drugs. Its pivotal role has been ascertained in clinical trials in lung, breast, and ovarian cancer, three diseases that can be successfully treated with microtubule-interacting drugs. Although TUBB3 is probably not a unique factor in drug resistance, the hope is that direct targeting of this protein will increase the response to microtubule-interacting drugs, thereby overcoming an important element in the growth of drug resistance.
Export Options
About this article
Cite this article as:
Ferlini Cristiano, Raspaglio Giuseppina, Cicchillitti Lucia, Mozzetti Simona, Prislei Silvia, Bartollino Silvia and Scambia Giovanni, Looking at Drug Resistance Mechanisms for Microtubule Interacting Drugs: Does TUBB3 Work?, Current Cancer Drug Targets 2007; 7 (8) . https://dx.doi.org/10.2174/156800907783220453
DOI https://dx.doi.org/10.2174/156800907783220453 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets Inflammation and Pancreatic Cancer: Recent Development with Focusing on Potential New Drug Targets
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The In-Situ One-Step Synthesis of a PDC Macromolecular Pro-Drug and the Fabrication of a Novel Core-Shell Micell
Current Pharmaceutical Design The Promising Signatures of Circulating microRNA-145 in Epithelial Ovarian Cancer Patients
MicroRNA Catheter Related Line Sepsis Resulting from Mycobacterium <i>chelonae</i> Infection in an Immunocompromised Host
Infectious Disorders - Drug Targets Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights
MicroRNA Non-Viral Gene Delivery Methods
Current Pharmaceutical Biotechnology Antagonizing the Calcium-Sensing Receptor: Towards New Bone Anabolics?
Current Molecular Pharmacology Unfoldomics of Human Genetic Diseases: Illustrative Examples of Ordered and Intrinsically Disordered Members of the Human Diseasome
Protein & Peptide Letters Sodium Dependent Multivitamin Transporter (SMVT): A Potential Target for Drug Delivery
Current Drug Targets Brachytherapy: State of the Art and Possible Improvements
Anti-Cancer Agents in Medicinal Chemistry Inhibition of EGFR Signaling by N-cyclohexyl-2-(1-(phenylsulfonyl)piperidin-4-yl) acetamide
Anti-Cancer Agents in Medicinal Chemistry Current RNA-based Therapeutics in Clinical Trials
Current Gene Therapy Triple-negative Breast Cancer and Poly(ADP-ribose) Polymerase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Characterization of Stem-Like Cells Directly Isolated from Freshly Resected Laryngeal Squamous Cell Carcinoma Specimens
Current Stem Cell Research & Therapy Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology Oxidovanadium(IV) Complex Disrupts Mitochondrial Membrane Potential and Induces Apoptosis in Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry